Corcept Therapeutics

Corcept Therapeutics Inc. is a pharmaceutical company developing products that regulate the effects of cortisol (the stress hormone) and deal with severe metabolic disorders.[1] The company is a publicly traded company on NASDAQ under the symbol "CORT".

Corcept Therapeutics Inc.
Public
Traded as NASDAQ:CORT
Industry Pharmaceutical Industry
Founded 1998[2]
Headquarters United States
Products Pharmaceutics
Website www.corcept.com

Treatments

Corcept Therapeutics Inc. has developed treatments mainly focusing on solving metabolic disorders and related problems, and have several experimental and on-sale drugs released.[3]

Type II diabetes

One of the principle drugs that the company has been developing is Korlym, which is an oral daily medication for patients with type II diabetes mellitus or glutose intolerance, and those who failed or might not be appropriate to be under surgery. In 2013, after being offered since 2012 in the US, the drug was further commercialized to the market outside the States and reached the global medical field, since the company's partnership with Idis Access Program was approved and launched.[4] this is the first therapy approved by US Food and Drug Administration (FDA) for patients with endogenous Cushing's syndrome.[5]

Psychotic depression

From 1998, the company has been studying the psychotic features of depression and developing oral medication for the symptoms. In recent years, two of the main trials were conducted with the drug CORLUX, which is a once-daily treatment given to patients, mainly in the United States.[6]

Other metabolic disorders

The company has also been studying treatment for other metabolic disorders. In April 2005, results of two preclinical studies were announced by the company, demonstrating an effect that can prevent weight gain associated with treatment with olanzapine.[7]

In December 2013, the company announced plans to extend its development program for glucocorticoid receptor (GR) antagonists, including mifepristone, into oncology.[8]

Patent rights

In December 2013, Corcept Therapeutics Inc. licensed patent rights with the University of Chicago's Center for Technology Development & Ventures, and started investigating new drug application with the US Food and Drug Administration (FDA), on metastatic triple-negative breast cancer (TNBC).[9]

References

  1. ↑ http://www.corcept.com/
  2. ↑ http://finance.yahoo.com/q/pr?s=CORT+Profile
  3. ↑ https://www.google.com/finance?cid=660571
  4. ↑ http://www.reuters.com/finance/stocks/CORT.O/key-developments/article/2800010
  5. ↑ http://www.corcept.com/products
  6. ↑ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=CORT.O
  7. ↑ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=CORT.O
  8. ↑ "Corcept Therapeutics Announces Oncology Development Program".
  9. ↑ http://www.prnewswire.com/news-releases/CORTmed-announces-acquisition-of-zipsor-diclofenac-potassium-from-xanodyne-pharmaceuticals-Inc.-159919525.html

External links

This article is issued from Wikipedia - version of the 11/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.